Carbetocin for the reduction of blood loss during myomectomy
- Conditions
- myomectomy surgery
- Registration Number
- PACTR201908793583382
- Lead Sponsor
- faculty pf medicine suez canal university
- Brief Summary
Total blood loss was significantly lower in the Carbetocin group (399.27 ± 28.94 ml) than the tranexamic acid group (535.15 ± 80.30 ml) (p <0.001). Intra-operative blood loss was significantly lower in the Carbetocin group (371.39 ± 27.54 ml) than the tranexamic acid group (478.48 ± 60.4 ml) (p <0.001). Post-operative blood loss was significantly lower in the Carbetocin group (27.88 ± 32.32 ml) than the tranexamic acid group (56.67 ± 53.13 ml) (p 0.001).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 132
age ranging from 18 to 50 years with documented uterine fibroids on pelvic imaging (pelvic ultrasound or MRI) within last 12 months,
- patients complaining of abnormal vaginal bleeding, chronic pelvic pain, pressure symptoms or reproductive disorders
- pre-operative hemoglobin > 8g/dl.
- post-menopausal women
- patients previously treated with Depo-Lupron, Depo-Provera or oral contraceptive pills,
- patients with known bleeding/clotting disorders, active liver, kidney or cardiovascular disease or receiving anticoagulant, NSAIDs or antiplatelet,
- previous history of gynecological malignancy,
- previous abdominal myomectomy or venous thromboembolism.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Studying the effect of tranexamic acid versus carbetocin on operative blood loss ( intra-and post operative ) and the needs of blood transfusion in women undergoing myomectomy.
- Secondary Outcome Measures
Name Time Method the need for blood transfusion, patients hemoglobin level after the operation